|
|
Volumn 388, Issue 10044, 2016, Pages 533-
|
|
Lung cancer: despite advances, prevention is still best
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALECTINIB;
ANTINEOPLASTIC AGENT;
CERITINIB;
CRIZOTINIB;
ERLOTINIB;
NIVOLUMAB;
PEMBROLIZUMAB;
PROGRAMMED DEATH 1 LIGAND 1;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER IMMUNOTHERAPY;
CANCER INCIDENCE;
CANCER MORTALITY;
CANCER PREVENTION;
CANCER RADIOTHERAPY;
CANCER RISK;
CANCER SCREENING;
CANCER SURGERY;
CANCER SURVIVAL;
CANCER THERAPY;
CENTRAL NERVOUS SYSTEM METASTASIS;
COMPUTER ASSISTED TOMOGRAPHY;
EDITORIAL;
GENE MUTATION;
HEALTH CARE QUALITY;
HIGH INCOME COUNTRY;
HIGH RISK POPULATION;
HUMAN;
LUNG CANCER;
MIDDLE INCOME COUNTRY;
MOLECULARLY TARGETED THERAPY;
MULTIPLE CANCER;
NON SMALL CELL LUNG CANCER;
OPTIMISM;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
POPULATION;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SMOKING;
THORAX RADIOGRAPHY;
TOBACCO;
VIDEO ASSISTED THORACOSCOPIC SURGERY;
ADVERSE EFFECTS;
COST BENEFIT ANALYSIS;
EARLY CANCER DIAGNOSIS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
ANTINEOPLASTIC AGENTS;
COST-BENEFIT ANALYSIS;
EARLY DETECTION OF CANCER;
HUMANS;
IMMUNOTHERAPY;
LUNG NEOPLASMS;
SMOKING;
|
|
EID: 84992013430
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(16)31260-0 Document Type: Editorial |
|
Times cited : (7)
|
|
References (0)
|